Urine-based liquid biopsy markers for diagnosis and treatment response monitoring in higher-stage bladder cancer

Urine is in direct contact with bladder tumors, making it an ideal biofluid for non-invasive biomarker discovery. This study aimed to identify urine-based protein biomarkers for bladder cancer diagnosis and treatment response monitoring. By analyzing transcriptomic data from bladder cancer cell lines with differential sensitivity to chemotherapy and radiotherapy, we identified four secreted proteins associated with treatment resistance: collagen type I alpha 1 chain (COL1A1), microfibrillar-associated protein 5 (MFAP5), dipeptidyl-peptidase 4 (DPP4), and extracellular matrix protein 1 (ECM1). Urinary concentrations were quantified by enzyme-linked immunosorbent assay (ELISA) in 57 bladder cancer patients and 22 cancer-free controls. All four markers were significantly elevated in patients, and a combined four-marker panel outperformed individual markers (area under the curve [AUC] = 0.916, 95% confidence interval [CI] = 0.858–0.975), with discrimination driven primarily by stage T1 or higher disease. In a treatment-monitoring cohort of 13 patients receiving systemic chemotherapy and/or radiotherapy, changes in urinary COL1A1, MFAP5, and ECM1 from baseline were concordant with CT-based response, with COL1A1 showing the highest concordance (92.3%). These exploratory findings suggest that urinary secreted proteins may reflect disease status during treatment. However, their added value over imaging was not assessed, and their utility in surveillance settings warrants future investigation.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-18
DOI
https://doi.org/10.1038/s41598-026-78109-w
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urine-based liquid biopsy markers for diagnosis and treatment response monitoring in higher-stage bladder cancer

Da‐Young Eum, Mi-So Jeong, Ja Yoon Ku, Soon Yong Park et al.
Scientific Reports
Bladder and Urothelial Cancer Treatments
article

Urine-based liquid biopsy markers for diagnosis and treatment response monitoring in higher-stage bladder cancer

Da‐Young Eum, Mi-So Jeong, Ja Yoon Ku, Soon Yong Park, Seung-Woo Baek, Kyu Heo, Jin Hoon Cho, Soo Young Chung, Si Ho Choi, Joo Yeon Song, Sung Hee Jung, Yoo-Jin Choi, Gunwoo Kim
article en

Abstract

Urine is in direct contact with bladder tumors, making it an ideal biofluid for non-invasive biomarker discovery. This study aimed to identify urine-based protein biomarkers for bladder cancer diagnosis and treatment response monitoring. By analyzing transcriptomic data from bladder cancer cell lines with differential sensitivity to chemotherapy and radiotherapy, we identified four secreted proteins associated with treatment resistance: collagen type I alpha 1 chain (COL1A1), microfibrillar-associated protein 5 (MFAP5), dipeptidyl-peptidase 4 (DPP4), and extracellular matrix protein 1 (ECM1). Urinary concentrations were quantified by enzyme-linked immunosorbent assay (ELISA) in 57 bladder cancer patients and 22 cancer-free controls. All four markers were significantly elevated in patients, and a combined four-marker panel outperformed individual markers (area under the curve [AUC] = 0.916, 95% confidence interval [CI] = 0.858–0.975), with discrimination driven primarily by stage T1 or higher disease. In a treatment-monitoring cohort of 13 patients receiving systemic chemotherapy and/or radiotherapy, changes in urinary COL1A1, MFAP5, and ECM1 from baseline were concordant with CT-based response, with COL1A1 showing the highest concordance (92.3%). These exploratory findings suggest that urinary secreted proteins may reflect disease status during treatment. However, their added value over imaging was not assessed, and their utility in surveillance settings warrants future investigation.

Scientific Reports
Dongnam Institute of Radiological & Medical Sciences (KR), Korea Research Institute of Bioscience and Biotechnology (KR)
Dong-A University
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon